NY DOH Announces $20M for Abortion Health Care Services
The New York State Department of Health has announced a new $20 million funding opportunity for abortion health care services through the Supplemental Abortion Provider Support Fund. Letters have been issued to 22 potential awardees notifying them of their eligibility for these state grants.
EMA Enhances PRIME Scheme to Accelerate Medicine Development
The European Medicines Agency (EMA) has launched three new features for its PRIME scheme, designed to accelerate the development of medicines targeting unmet medical needs. These tools aim to streamline scientific dialogue and provide developers with faster answers and better preparation for marketing authorisation applications.
Texas Medical Board Suspends Physician License for Child Pornography
The Texas Medical Board has temporarily suspended the medical license of An Q. Van, M.D., effective immediately, due to his arrest for possession of child pornography. A hearing will be held to determine further action regarding his license.
Alabama DPH Highlights Risks of Cannabinoid Products During Poison Prevention Week
The Alabama Department of Public Health issued a notice highlighting the risks associated with cannabinoid products, particularly for children, during National Poison Prevention Week. In 2025, the Alabama Poison Information Center managed 469 cases involving cannabinoid exposures.
Tennessee Department of Health Reinforces Naloxone Importance Amid Cychlorphine Fatalities
The Tennessee Department of Health issued a notice reinforcing the importance of naloxone due to over 30 fatal overdoses linked to cychlorphine since October 2025. The notice provides information on recognizing opioid overdoses and administering naloxone, which is effective but may require repeat dosing.
Rural Health Workforce Retention Funding Opportunity
North Dakota Health and Human Services announced a new funding opportunity for its Rural Health Transformation Program, offering approximately $10 million to support the retention of healthcare professionals in critical access hospitals. The application deadline is April 30, 2026.
Health Canada Task Force on Pharmaceutical Access and Innovation
Health Canada and Innovation, Science and Economic Development Canada have launched a joint Pharmaceutical and Life Sciences Sector Task Force. The task force will support access to pharmaceuticals and identify solutions to drive innovation and growth in the Canadian life sciences sector.
Recreational Water Advisory Partially Lifted in Montgomery County
Maryland health officials announced the partial lifting of a recreational water advisory in Montgomery County, impacted by a recent sewage spill. The advisory has been lifted for areas downriver from the spill site, beginning with Lock 8, based on acceptable E.coli bacteria levels.
Oregon WIC Annual Report Highlights Program Impact
The Oregon Health Authority released its 2025 annual report for the Women, Infants, and Children (WIC) program. The report highlights increased WIC benefit spending, expanded food options, and improved access in rural communities, underscoring the program's role in supporting healthy families and local economies.
HHS Recognizes Poison Prevention Week
The North Dakota Health and Human Services (HHS) is recognizing Poison Prevention Week to raise awareness about poisoning risks and prevention. In 2025, the North Dakota Poison Help line received over 5,800 calls from residents, primarily concerning medications.
FDA Early Alert: Handy Solutions Heating Pad Issue
The FDA issued an Early Alert regarding a potentially high-risk issue with Handy Solutions Neck & Shoulders Heating Pads manufactured by Navajo Manufacturing Company. The device can overheat and cause burns or property damage, with four serious injuries reported.
New Mexico Health Officials Warn of Heat Illness
New Mexico health officials have issued a warning about heat illness due to rising temperatures expected to exceed 90 degrees. The notice highlights vulnerable populations and provides preventative measures. Last summer, there were 834 heat-related emergency department visits in the state.
HSA Warns Public About Products with Banned or Potent Medicinal Ingredients
The Health Sciences Authority (HSA) in Singapore has issued a warning regarding four products found to contain banned or potent medicinal ingredients, including steroids and sibutramine. Three consumers experienced serious adverse effects after consuming these products. HSA is working to remove listings and investigate sellers.
Palliative Care Council Meeting Notice
The Ohio Department of Health has issued a notice for an upcoming public meeting of the Palliative Care and Quality of Life Interdisciplinary Council. The meeting is scheduled for March 26, 2026, in Columbus, Ohio, and is open to the public.
CMS Medicare Data Application for Performance Measurement Comment Period
The Centers for Medicare and Medicaid Services (CMS) is seeking public comment on its intention to collect information related to Medicare data applications for performance measurement. This notice is part of the Paperwork Reduction Act process, requiring a 60-day public comment period.
CMS Seeks Public Comment on Information Collection
The Centers for Medicare & Medicaid Services (CMS) is seeking public comment on its intention to collect information from the public under the Paperwork Reduction Act. The notice provides a 60-day comment period for interested parties to submit feedback on the proposed information collection.
FDA Indexes New Drug for Ornamental Finfish Parasites
The FDA has added Prazi-Med, a praziquantel powder for immersion, to the Index of Legally Marketed Unapproved New Animal Drugs for Minor Species. This drug treats internal and external parasites in ornamental finfish, providing a faster and less expensive pathway to market for such products.
WHO Report: Child Mortality Slows, 4.9 Million Die Before Five
A new UN report indicates that while child deaths have fallen globally since 2000, the pace of reduction has slowed significantly since 2015. In 2024, 4.9 million children died before their fifth birthday, with preventable causes like malnutrition and infectious diseases being major factors. The report highlights disparities in healthcare access, particularly in sub-Saharan Africa and conflict-affected regions.
Atropine Eye Drops: Medication Error Risk in Children Under 3
The French National Agency for Medicines and Health Products Safety (ANSM) has issued a notice regarding the risk of medication errors with atropine eye drops in children under 3 years old. The notice highlights specific risks and provides recommendations to prevent these errors.
NIOSH Seeks Public Comment on Draft Lewisite IDLH Value Profile
The CDC's NIOSH is requesting public comment on a draft Immediately Dangerous to Life or Health (IDLH) Value Profile document for the chemical lewisite. The comment period closes on May 18, 2026.
CDC Draft IDLH Value Profile for Lewisite
The CDC has released a draft Immediately Dangerous to Life or Health (IDLH) value profile for Lewisite. This document is open for public comment and provides scientific information to inform occupational safety standards.
ANSM Safety Alert: B. Braun Infusion Sets and Mentor Tissue Expanders
The ANSM has issued a safety alert regarding specific lots of B. Braun infusion sets and Mentor tissue expanders. A lot recall has been implemented by the manufacturer, B. Braun Medical Inc., and Mentor. Affected users have been notified.
ANSM Safety Alert for Soltive SuperPulsed Laser Systems
The French ANSM has issued a safety alert (R2607992) regarding Soltive SuperPulsed laser systems, following a security action initiated by Olympus. Affected users have been notified directly by the manufacturer.
SC Board of Pharmacy: Revised Vaccine Administration Protocol
The South Carolina Board of Pharmacy has revised its protocol for vaccine administration by pharmacists, effective September 17, 2025. The primary change allows pharmacists, interns, and technicians to administer FDA-approved COVID-19 vaccines without a practitioner's order, following specific professional recommendations.
Idaho Pharmacy Board: Ivermectin OTC Update
The Idaho Board of Pharmacy has issued an update regarding the over-the-counter availability of Ivermectin. This notice clarifies regulatory standing following legislative changes, referencing Senate Bill 1211.
Idaho Board of Pharmacy Grants Medication Authority to Naturopaths
The Idaho Board of Pharmacy has announced that naturopaths are now granted medication authority. This change expands the scope of practice for licensed naturopathic physicians in Idaho, allowing them to prescribe certain medications.
Idaho Pharmacy Licensure Renewal Cycle and Fee Updates
The Idaho Board of Pharmacy is updating its licensure renewal cycles and fees effective July 1, 2025. Pharmacist licenses will now expire on the licensee's birthday, with renewals shifting to a two-year cycle, and associated fees will double for biennial renewals.
Idaho Board of Pharmacy: Expedited Temporary Licensure Pathway for Rite Aid Closure
The Idaho Board of Pharmacy has established an expedited temporary licensure pathway due to the closure of Rite Aid pharmacies. This pathway aims to ensure continuity of pharmaceutical services for patients affected by the closures.
CMS Seeks Public Comment on Information Collection Activities
The Centers for Medicare & Medicaid Services (CMS) is seeking public comment on its intention to collect information, specifically regarding the State-based Exchange Annual Reporting Tool (SMART). This notice is part of the Paperwork Reduction Act process, allowing for public input on the necessity and utility of the proposed information collection.
CMS Seeks Public Comment on Information Collection Proposals
The Centers for Medicare & Medicaid Services (CMS) is seeking public comment on its intention to collect information from the public, as required by the Paperwork Reduction Act. This notice provides an opportunity for stakeholders to comment on proposed information collections, including revisions to existing ones.
FDA Draft Guidance on Alternatives to Animal Testing in Drug Development
The FDA has issued draft guidance to assist drug developers in validating new approach methodologies (NAMs) as alternatives to animal testing in drug development. This guidance supports the FDA's roadmap to reduce animal testing and bring safe, effective drugs to market sooner.
Colorado Food Program Highlights Success and Urges Provider Enrollment
The Colorado Department of Public Health and Environment is highlighting the success of the Colorado Food Program, which serves over 15 million meals annually. The department is encouraging new child and adult day care centers to enroll in the federal initiative to receive reimbursement for nutritious meals.
CMS Agency Information Collection Activities Proposed for Public Comment
The Centers for Medicare & Medicaid Services (CMS) is seeking public comment on proposed information collections under the Paperwork Reduction Act. The comment period is open for 60 days, closing on May 18, 2026.
CMS Seeks Public Comment on Information Collection Activities
The Centers for Medicare & Medicaid Services (CMS) is requesting public comment on its intention to collect information from the public, as required by the Paperwork Reduction Act. This notice provides an opportunity for comment on the necessity, utility, and burden of proposed information collections.
FDA Guidance on Topical Drug Product Characterization for ANDAs
The FDA has issued a final guidance document for industry on the physicochemical and structural characterization of topical drug products submitted in abbreviated new drug applications (ANDAs). This guidance provides recommendations to assist applicants in identifying dosage forms and describing critical performance properties to support bioequivalence demonstrations for generic topical products.
FDA Advisory Committee Renewal: Obstetrics, Reproductive and Urologic Drugs
The Food and Drug Administration (FDA) has announced the renewal of the Obstetrics, Reproductive and Urologic Drugs Advisory Committee for an additional two years. The committee's charter will now be in effect until March 23, 2028, continuing its role in advising on drug safety and effectiveness.
FDA Determination: Methergine Injection Not Withdrawn for Safety or Effectiveness
The FDA has determined that Methergine (methylergonovine maleate) injection was not withdrawn from sale for safety or effectiveness reasons. This determination allows the FDA to approve abbreviated new drug applications (ANDAs) for generic versions of this product, provided other requirements are met.
FDA Notice: Preparation for Cosmetics Regulation Meeting and Request for Comments
The FDA is requesting public comments to prepare for the twentieth International Cooperation on Cosmetics Regulation (ICCR-20) annual meeting. The input will help inform the agency's participation in discussions on cosmetics regulation. Comments are due by May 18, 2026.
OTC Monograph Drug Facility Fee Rates for FY 2026
The FDA has published the Over-the-Counter (OTC) Monograph Drug Facility (MDF) fee rates for fiscal year 2026. These fees are authorized by the Over-the-Counter Monograph Drug User Fee Amendments (OMUFA II) and support FDA's OTC monograph drug activities.
FDA: Gluten Labeling and Cross-Contact Comment Period Extension
The Food and Drug Administration (FDA) has extended the public comment period for its request for information regarding gluten labeling and preventing cross-contact in packaged foods. The original notice was published on January 22, 2026, and the comment period is now extended to April 22, 2026.
Center for Scientific Review Amended Meeting Notice
The National Institutes of Health (NIH) has issued an amended notice regarding a meeting of the Clinical Management in General Care Settings Study Section. The amendment changes the Scientific Review Officer (SRO) for the meeting, which is closed to the public.
NIGMS Notice of Partially Closed Meetings
The National Institutes of Health (NIH) has issued a notice regarding upcoming partially closed meetings of the National Advisory General Medical Sciences Council. The meetings are scheduled for May 21, 2026, and September 10, 2026, and will include both open sessions for program discussions and closed sessions for grant application reviews.
Center for Scientific Review; Amended Notice of Meeting
The National Institutes of Health (NIH) has amended a notice regarding a meeting of the HIV Comorbidities and Clinical Studies Study Section. The meeting, originally scheduled for two days, has been changed to a single day on March 27, 2026. The meeting remains closed to the public.
National Institute of Diabetes and Digestive and Kidney Diseases: Amended Meeting Notice
The National Institutes of Health (NIH) has issued an amended notice regarding a meeting for the Board of Scientific Counselors, National Institute of Diabetes and Digestive and Kidney Diseases (DKBSC). The meeting dates have been rescheduled from March 30-31, 2026, to June 10-11, 2026.
OMB Review Request for Hazardous Waste Worker Training Data Collection
The National Institutes of Health (NIH) is requesting public comment on a proposed data collection project related to its Hazardous Waste Worker Training Program. This notice is part of the process for submitting the collection to the Office of Management and Budget (OMB) for review and approval.
Center for Scientific Review Notice of Closed Meetings
The National Institutes of Health (NIH) has published a notice announcing upcoming closed meetings for various review committees. These meetings are scheduled for April 2026 and will involve the review and evaluation of grant applications.
DEA: Xylazine Involved in 6,096 Overdose Deaths in 2023
The DEA issued a public safety alert stating that xylazine was involved in 6,096 overdose deaths in 2023, making it the fourth most common drug in such fatalities. The alert indicates that all 50 states have reported the presence of xylazine in the illicit drug supply.
CDC Request for Comment on Draft IDLH Value Document for Lewisite
The CDC's National Institute for Occupational Safety and Health (NIOSH) is requesting public comment on a draft Immediately Dangerous to Life or Health (IDLH) Value Profile document for the chemical lewisite. The comment period closes on May 18, 2026.
DEA Announces Multiple Drug Enforcement Actions and Arrests
The DEA has announced multiple drug enforcement actions and arrests across various field divisions, including significant seizures of illicit funds and convictions for drug trafficking and money laundering. These actions highlight ongoing efforts to combat transnational criminal organizations and dismantle drug distribution networks.
HRSA - Delta States Rural Development Grant Program Information Collection Revision
The Health Resources and Services Administration (HRSA) is seeking public comment on a proposed revision to the Delta States Rural Development Network Grant Program's information collection request. This revision aims to modify how race and ethnicity measures are displayed in the data collection platform.
HRSA Countermeasures Injury Compensation Program Information Collection Revision
The Health Resources and Services Administration (HRSA) has submitted a revised Information Collection Request (ICR) for the Countermeasures Injury Compensation Program (CICP) to the Office of Management and Budget (OMB) for approval. This notice requests public comments on the revisions, which aim to improve efficiency and data quality.
FDA Final Guidance on Topical Drug Product Characterization for ANDAs
The FDA has issued final guidance for industry on the physicochemical and structural characterization of topical drug products submitted in Abbreviated New Drug Applications (ANDAs). This guidance assists applicants in identifying generic topical products and supporting bioequivalence demonstrations. It finalizes the draft guidance issued in October 2022.
AMA Applauds Bill Exempting Physicians from H-1B Visa Fee
The American Medical Association (AMA) is applauding the introduction of bipartisan legislation that would exempt physicians and other health care professionals from a $100,000 filing fee on new H-1B visa petitions. This action aims to alleviate costs for hiring medical professionals and address physician shortages.
FDA Complaint Consultation
The FDA has posted a complaint for public comment, with the comment period closing on March 17, 2026. This action allows stakeholders to provide input on the complaint's content.
FDA Closes Comment Period for Blueroot Health Nutrient Submission
The FDA has closed the public comment period for a nutrient submission from Blueroot Health concerning their B6 + B Complex product. The submission was related to energy metabolism support. No further action is required from the public at this time.
FDA - Swanson Health Products Menopause Support
The FDA has posted a document related to Swanson Health Products' Menopause Support supplement. The document, identified as FDA-2025-S-0024-1968, is available for review on the Regs.gov platform. No specific regulatory action or compliance requirement is detailed in the provided information.
Harmony Foods Multivitamin Gummies - FDA Docket
The FDA has opened Docket FDA-2025-S-0024 concerning Harmony Foods Multivitamin Gummies. An attachment from Harmony Foods LLC provides details on their Meijer Wellness Women's Multivitamin Gummies.
FDA Complaint Document
The FDA has posted a complaint document to the Regs.gov portal. The document, authored by CTP, is available for review and download. No specific details regarding the nature of the complaint or its implications are provided in the metadata.
FDA Complaint Document
The FDA has posted a complaint document related to FDA-2026-H-2575-0001. The document was made available on March 17, 2026, and is authored by CTP.
FDA Acknowledgment Letter to Lusonix Group
The FDA has posted an acknowledgment letter sent to Lusonix Group regarding a submission. The letter, authored by CDRH, confirms receipt of materials but provides no further details on the nature of the submission or any regulatory actions.
Luxsonix Group Variance Approval Letter
The FDA has issued a variance approval letter to Luxsonix Group. This notice pertains to a specific variance granted by the Center for Devices and Radiological Health (CDRH).
FDA Consultation on i-Health Inc. Culturelle Gummies
The FDA has opened a comment period regarding i-Health Inc.'s Culturelle Women's Probiotic + Multivitamin Gummies. This consultation seeks public input on the product, with specific details available via the provided link.
FDA: L-Theanine Powder Supports Relaxation Claim
The FDA has received a submission regarding L-Theanine Powder, specifically from Threshold Enterprises (Source Naturals), for its product that claims to support relaxation and ease everyday stress. This notice indicates a submission for a dietary supplement claim.
FDA - Vitanica BreastBlend Claim Review
The FDA has received a submission regarding Vitanica's BreastBlend product, which claims to support healthy breast tissue. This notice indicates the FDA is aware of the product and its claims, but no specific regulatory action or enforcement is detailed in the provided information.
FDA - Better Being Co. Solaray StressMag Product Information
The FDA has posted information regarding Better Being Co.'s Solaray StressMag product, which claims to support mood and relaxation. This filing appears to be a notification or informational submission related to a specific product. No new regulations or enforcement actions are detailed.
FDA - Harmony Foods LLC. Meijer Fiber Gummies Submission
Harmony Foods LLC. has submitted information regarding their Meijer Fiber Gummies 72ct product to the Food and Drug Administration (FDA). This submission is part of the agency's regulatory process for food products.
FDA Submission for Harmony Foods Magnesium Citrate Gummies
The FDA has received a submission from Harmony Foods LLC regarding their Meijer Magnesium Citrate Gummies. This notice pertains to a product submission and does not contain new regulatory requirements or guidance.
FDA Document on GreenBio Nutrients Joint Health Capsules
The FDA has posted a document related to GreenBio Nutrients Inc.'s ILEXPOWER and JointAlive Capsules. The document is available for review on the Regs.gov platform. No specific regulatory action or compliance requirement is detailed in the provided information.
Harmony Foods B12 Gummies Docket Information
The FDA has posted docket information for Harmony Foods LLC concerning their Free & Pure Zero Sugar B12 Gummies. This notice provides access to supporting documentation related to the product, as filed with the agency.
FDA Submission: Bio Minerals N.V. Biosil Daily Beauty Protein Vanilla
The FDA has received a submission from Bio Minerals N.V. regarding their product, Biosil Daily Beauty Protein Vanilla. This submission is part of the agency's regulatory process for new product information.
FDA - Blueroot Health Submission on Respiratory and Immune Function
The FDA has received a submission from Blueroot Health regarding their product, Vital Nutrients, Aller-C, which is intended to support healthy respiratory and immune function. This submission is part of the public record available on Regulations.gov.
FDA CDRH Variance Approval Letter for Photon GFX
The FDA's Center for Devices and Radiological Health (CDRH) has issued a variance approval letter to Photon GFX. This notice indicates a specific approval for a medical device variance, though no further details or documents are available for review.
FDA Filing: New Chapter Women's 50+ Multivitamin
The FDA has received a filing from New Chapter regarding their Women's 50+ Multivitamin. This filing pertains to a product supporting immune function, cellular energy, and antioxidants for healthy aging. No specific compliance actions or deadlines are indicated in this notice.
FDA Complaint Document
The FDA has posted a complaint document to the Regs.gov portal on March 17, 2026. The document is available for public viewing and download via the provided link.
FDA Variance Application from Alpha-Omega Services
The FDA has received a variance application from Alpha-Omega Services, Inc. The application pertains to medical device regulations. Further details are available via the provided URL.
FDA Complaint Document
The FDA has posted a complaint document related to FDA-2026-H-2311-0001. The document is available for review on the Regs.gov platform. No further details on the nature of the complaint or its implications are provided.
FDA GRAS Notice 1288 Amendment for Steviol Glycosides
The FDA has posted an amendment to GRAS Notice 1288 concerning enzyme-modified steviol glycosides. This notice is from the manufacturer and is part of the Generally Recognized As Safe (GRAS) notification process.
FDA CDER Response Letter to Hyman, Phelps & McNamara
The FDA's Center for Drug Evaluation and Research (CDER) has posted a response letter addressed to the law firm Hyman, Phelps & McNamara, P.C. The document was made available on March 17, 2025, through the Regs.gov portal. No other details regarding the content of the response are provided.
Ashley County Health Unit Closure and Service Relocation
The Arkansas Department of Health has announced the temporary closure of the Ashley County Health Unit in Crossett due to storm damage. All services previously offered at the Crossett location have been relocated to the Ashley County Health Unit in Hamburg.
South Carolina Measles Outbreak Update
The South Carolina Department of Public Health reported one new measles case, bringing the total outbreak count to 997. The update also provided data on age breakdown and vaccination status of cases. Vaccination is emphasized as the best prevention method.
Medicare Diabetes Prevention Program Expanded Model Booklet
CMS has released a booklet detailing the Medicare Diabetes Prevention Program Expanded Model. This guidance explains how healthcare providers can enroll as Medicare-enrolled MDPP suppliers to help patients with prediabetes reduce their risk of developing diabetes.
Hospital Price Transparency Requirements and Resources Fact Sheet
The Centers for Medicare & Medicaid Services (CMS) has released a fact sheet detailing hospital price transparency requirements. This document outlines the pricing information hospitals must provide and offers resources to assist them in meeting accessibility and file requirements.
CMS IDTF Booklet: Program, Enrollment, and Billing
The Centers for Medicare & Medicaid Services (CMS) has released a new booklet providing an overview of the Independent Diagnostic Testing Facility (IDTF) program. The publication covers program details, enrollment requirements, and billing issues for IDTFs.
Medicare Coverage of Diabetes Supplies
CMS has released a fact sheet detailing Medicare coverage for diabetes supplies under Part B and Part D. The guidance clarifies which supplies and services are covered and which are not, aiming to inform beneficiaries and providers.
Intravenous Immune Globulin Items, Services, Billing, and Coding
The Centers for Medicare & Medicaid Services (CMS) has released a fact sheet detailing coverage, supplier eligibility, billing, and coding requirements for Intravenous Immune Globulin (IVIG) items and services. This guidance aims to clarify program integrity and claims processing for providers.